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Activation of E-prostanoid 3 receptor
in macrophages facilitates cardiac healing
after myocardial infarction
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Shengkai Zuo1, Bo Tao1, Yu Yu1, Junwen Wang3,5,6, Michael Lazarus7 & Ying Yu1,2
Two distinct monocyte (Mo)/macrophage (Mp) subsets (Ly6Clow and Ly6Chigh) orchestrate
cardiac recovery process following myocardial infarction (MI). Prostaglandin (PG) E2 is
involved in the Mo/Mp-mediated inﬂammatory response, however, the role of its receptors in
Mos/Mps in cardiac healing remains to be determined. Here we show that pharmacological
inhibition or gene ablation of the Ep3 receptor in mice suppresses accumulation of Ly6Clow
Mos/Mps in infarcted hearts. Ep3 deletion in Mos/Mps markedly attenuates healing after MI
by reducing neovascularization in peri-infarct zones. Ep3 deﬁciency diminishes CX3C
chemokine receptor 1 (CX3CR1) expression and vascular endothelial growth factor (VEGF)
secretion in Mos/Mps by suppressing TGFb1 signalling and subsequently inhibits Ly6Clow
Mos/Mps migration and angiogenesis. Targeted overexpression of Ep3 receptors in
Mos/Mps improves wound healing by enhancing angiogenesis. Thus, the PGE2/Ep3 axis
promotes cardiac healing after MI by activating reparative Ly6Clow Mos/Mps, indicating that
Ep3 receptor activation may be a promising therapeutic target for acute MI.
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H
ealing of the infarcted myocardium involves a complex
and coordinated process of inﬂammation, angiogenesis
and tissue remodelling. Monocytes (Mos) and macro-
phages (Mps) in the infarcted myocardium are the essential
immune cells for determining the progression and resolution of
inﬂammation and repair following myocardial infarction (MI)1.
Disruption of the Mo/Mp-mediated inﬂammatory response by
Mo/Mp depletion or inhibition of Mo/Mp migration impairs
wound healing and deteriorates left ventricular remodelling
after MI2–4. In contrast, controlled activation of Mos/Mps
ameliorates cardiac function and post MI remodelling by
inducing Mo/Mp inﬁltration and neovascularization5.
Two distinct subpopulations of Mos/Mps are involved in
recovery after MI in a sequential pattern. Early responding
Mos/Mps (Ly6Chigh) are predominant 1–3 days after MI and
display phagocytic and pro-inﬂammatory properties highly
expressing tumour necrosis factor (TNF) a, interleukin (IL-6),
myeloperoxidase, and cathepsins, whereas late-responding
Mos/Mps (Ly6Clow) appear 4–7 days after MI and exhibit
anti-inﬂammatory characteristics to support tissue regeneration
by secreting reparative cytokines, such as IL-10, transforming
growth factor (TGF) b1, and vascular endothelial growth factor
(VEGF)6. Injured hearts express a unique chemokine proﬁle
over time to coordinate Mo recruitment, and the sequential
recruitment of Ly6Chigh and Ly6Clow Mos is dependent on C–C
chemokine receptor type 2 (CCR2) and CX3C chemokine
receptor 1 (CX3CR1), respectively6. Moreover, Ly6Chigh Mos
can convert to Ly6Clow Mos in circulation7,8 and inﬂamed
tissues including infarcted hearts9,10. Delayed transition of
Ly6Chigh (M1-like) to Ly6Clow Mos/Mps (M2-like), such as in
atherosclerotic or diabetic animals11,12, attenuates wound repair
post MI. Thus, targeting certain Mos/Mps as a therapeutic
strategy for infarct healing and repair continues to receive
intensive attention13.
Prostaglandin (PG) E2 is a key lipid mediator in many
pathophysiological processes, including inﬂammation and
immune responses, and it elicits diverse functions by acting
on its four different E-prostanoid receptors (Ep1–Ep4)
in a paracrine and autocrine manner14. Microsomal PGE2
synthase-1 (mPGES-1), an inducible terminal isomerase for
PGE2 biosynthesis, is the major source of PGE2 formed in vivo
and during inﬂammatory responses15. Disabling PGE2
generation by mPGHS-1 deletion leads to increased infarct
sizes and adverse left ventricular remodelling after MI in mice16.
Interestingly, mice with mPGES-1 deletion in bone marrow-
derived myeloid cells alone displayssimilar cardiac phenotypes
in global mPGES-1-deﬁcient mice as subjected to coronary
ligation17, strongly implicating Mos/Mps-derived PGE2 in
wound healing after MI. However, the underlying mechanisms
are largely unknown.
In this study, we investigated the role of PGE2 receptors on
recruitment of Mo/Mp subsets during inﬂammation and further
explored effects of genetic deletion or overexpression of Ep3
receptor in Mos/Mps on cardiac healing in mice after acute MI.
We found, disruption of Ep3 receptor in Mos/Mps resulted in
augmented infarct size and reduced cardiac functions after MI
through suppression of reparative Ly6Clow inﬁltration and its
mediated angiogenesis in peri-infarct zones in mice. Moreover,
Ep3 deﬁciency in Mos/Mps inhibited TGFb1 signalling to directly
suppress transcription of Cx3cr1 and Vegf genes, therefore, retar-
ding Ly6Clow migration and neovascularization in the infarcted
hearts. Controlled activation of Ep3 receptor in Mos/Mps
facilitated Ly6Clow inﬁltration and subsequent healing of MI by
activation of TGFb1 signalling. Thus, PGE2/Ep3 axis facilites
cardiac healing after MI by activating reparative Ly6Clow
Mos/Mps.
Results
Ep3 mediates recruitment of Ly6Clow Mos/Mps in peritonitis.
To explore which PGE2 receptor subtype(s) mediate Mo/Mp
recruitment in zymosan-induced peritonitis in mice, both
Ly6Chigh and Ly6Clow Mos/Mps were sorted by ﬂow cytometry
(Fig. 1a). Western blot analysis conﬁrmed that the surface
markers CCR2 and CX3CR1 were abundantly expressed in
Ly6Chigh and Ly6Clow cells, respectively (Supplementary Fig. 1a),
and reverse transcriptase polymerase chain reaction (RT-PCR)
showed that more pro-inﬂammatory genes were expressed in
Ly6Chigh cells, while more reparative cytokines were expressed in
Ly6Clow cells (Supplementary Fig. 1b,c). All PGE2 receptors
(Ep1–4) were differentially expressed in both Ly6Chigh and
Ly6Clow Mos/Mps, and Ly6Clow Mos/Mps expressed more Ep1
and Ep3 receptors than Ly6Chigh Mos/Mps (Fig. 1b). Interest-
ingly, the Ep3 receptor inhibitor L-798,106 reduced peritoneal
inﬁltration of Ly6Clow and total Mos/Mps without signiﬁcantly
inﬂuencing Ly6Chigh Mos/Mps, while the Ep1 receptor inhibitor
SC-51322 retarded recruitment of Ly6Chigh Mos/Mps 48 h after
the zymosan challenge (Fig. 1c–e). Consistently, L-798,106 sig-
niﬁcantly suppressed expression of reparative and pro-angiogenic
cytokines (IL-13, TGFb1, VEGF and MMP9) and CX3CR1 in
inﬁltrated Mos/Mps (Fig. 1f) without markedly altering expres-
sion of pro-inﬂammatory cytokines (Fig. 1g). In addition, by
using myeloid cell-speciﬁc Ep3-deﬁcient mice (Ep3F/F;LysMCre,
Fig. 2a), we also found Ep3 deﬁciency in Mos/Mps (Fig. 2b)
markedly reduced total peritoneal Mos/Mps by restraining inﬁl-
tration of Ly6Clow Mos/Mps in response to a zymosan challenge
in mice (Fig. 2c–e). Similarly, Ep3 deletion downregulated
reparative cytokines and CX3CR1 gene expression in Mos/Mps
without overt effects on the expression of the pro-inﬂammatory
cytokines tested (Fig. 2f,g).
We then examined the effect of Ep3 deletion on the
differentiation of recruited Mos in zymosan-induced peritonitis
in mice. By day 1 after adoptive transfer (Supplementary Fig. 2a),
E30% of the accumulated Ly6Chigh Mos had Ly6Clow marker
(Supplementary Fig. 2b), while Ep3 deﬁciency did not signiﬁ-
cantly inﬂuence Ly6Chigh Mo inﬁltration (Supplementary Fig. 2c)
and its differentiation toward Ly6Clow Mos/Mps (Supplementary
Fig. 2d). In contrast, deletion of Ep3 receptor markedly reduced
inﬁltration of Ly6Clow Mos/Mps in zymosan-challenged perito-
neal cavity (Supplementary Fig. 2e,f). Taken together, these
results suggest that the Ep3 receptor is involved in mediating the
recruitment of Ly6Clow Mos/Mps in response to inﬂammatory
insults.
Ep3 promotes cardiac recovery by recruiting Ly6Clow Mo/Mp.
Two Mo/Mp subsets (Ly6Clow and Ly6Chigh) are also implicated
in recovery after MI—a sterile inﬂammatory reaction6. We then
examined the role of Mo/Mp in cardiac repair after ischaemia in
mice. As expected, all PG products, including PGE2, were elevated
in infarcted hearts, although Ep3 deﬁciency in Mos/Mps
had no signiﬁcant inﬂuence on PG production (Supplementary
Fig. 3a–e). CD11bþLy6GCD115þ Mos/Mps were sorted from
infarcted hearts in mice (Fig. 3a). Notably, total inﬁltrated
Mos/Mps in hearts were signiﬁcantly reduced in Ep3F/F;LysMCre
mice starting from 4 days after left anterior descending (LAD)
artery ligation compared with those in EP3F/F controls (Fig. 3b),
through suppression of recruitment of CD11bþLy6GCD115þ
Ly6Clow Mos/Mps (Fig. 3c) not CD11bþLy6GCD115þ
Ly6Chigh Mos/Mps (Fig. 3d), which was further conﬁrmed by
using additional F4/80 marker (Supplementary Fig. 4a–e).
While myeloid-Ep3 deﬁciency had no signiﬁcant effect on total
residential Mps in spleens, lungs, livers and hearts (Supple-
mentary Fig. 5a–d), and on circulating Mos and neutrophils in
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mice either (Supplementary Fig. 6a,b). Again, Mo adoptive
transfer conﬁrmed Ep3 deﬁciency resulted in decreased Ly6Clow
inﬁltration without overt inﬂuence on Ly6Chigh differentiation in
circulation and infracted hearts (Supplementary Fig. 7a–i). The
Ly6Clow Mo/Mp surface marker CX3CR1 and VEGF expression
in the inﬁltrated Mos/Mps were reduced by half in
Ep3F/F;LysMCre mice (Fig. 3e), and the CX3CR1 ligand CX3CL1
expression was not altered in hearts from Ep3F/F;LysMCre mice
(Supplementary Fig. 8a–c). Moreover, Ep3 deletion did not
inﬂuence proliferation and apoptosis of Mos/Mps inﬁltrated in
infarcted hearts (Supplementary Fig. 9a–d). Immunostaining
further conﬁrmed reduction of VEGF expression in Mos/Mps in
injured hearts in Ep3F/F;LysMCre mice (Fig. 3f,g). Accordingly, in
Ep3F/F;LysMCre mice, neovascularization in the ischaemic zone at
a late stage (day 14 after LAD ligation) was also dimini-
shed (Fig. 3h–j), infarct areas were expanded (Supplementary
Fig. 10a,b), and cardiac function recovery was markedly impaired
after MI (Fig. 3k,l, Supplementary Fig. 10c, Supplementary
Table 1). However, Ep3F/F;LysMCremice had normal cardiac
function at basal condition and even after dobutamine challenge
(Supplementary Table 2), and Ep3 deﬁciency did not inﬂuence
the number and functions of neutrophil inﬁltrated in the
infarcted hearts (Supplementary Fig. 11a–h).
Mps, as the major source of matrix metallopeptidases (MMPs)
and TGFb1, play an important role in cardiac remodelling and
ﬁbrosis18. Mo/Mp-Ep3 deletion, indeed, caused less non-vascular
smooth muscle actin (SMA) positive myoﬁbroblasts (Supple-
mentary Fig. 12a,b), downregulation of MMP9, collagen I, III and
Thrombospondin1 (THBS1) expression in infarcted hearts in
mice (Supplementary Fig. 12c–j). Consistently, Masson’s
trichrome staining showed an increased myocardial scar size
with decreased collagen deposition in Ep3F/F;LysMCre mice at
both day 7 and 14 after MI (Supplementary Fig. 13a–c). We did
not observe signiﬁcant difference of early necrotic area between
Ep3F/F;LysMCre and Ep3F/F mice after MI (Supplementary
Fig. 13d,e). Taken together, myeloid-Ep3 deletion impairs
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Figure 1 | Ep3 blockade represses recruitment of Ly6Clow Mos/Mps in peritonitis in mice. (a) Gating strategy for peritoneal Ly6Chigh and Ly6Clow
Mos/Mps in zymosan-induced peritonitis in mice. (b) Relative mRNA levels of the PG E2 receptors (Ep1–4) in peritoneal Ly6C
high and Ly6Clow Mos/Mps;
data represent mean±s.e.m. *Po0.05 versus Ly6ChighMos/Mps (unpaired two-tailed t-test); n¼ 5. (c–e) Effect of administration of different PGE2
receptor blockers on recruitment of total Mos/Mps (c), Ly6Chigh (d), and Ly6Clow (e) Mos/Mps at 48h and 96 h after a zymosan challenge in mice. Data
represent mean±s.e.m. *Po0.05 versus control(unpaired two-tailed t-test); n¼ 5–6. SC-51322, Ep1 inhibitor; AH6809, Ep2 inhibitor; L-798106, Ep3
inhibitor; L-161982, Ep4 inhibitor. (f,g) Effect of different PGE2 receptor blockers on expression of anti-inﬂammatory (f) and pro-inﬂammatory (g) markers in
peritoneal Mos/Mps collected 48 h after zymosan treatment. Data represent mean±s.e.m. *Po0.05 versus control (unpaired two-tailed t-test); n¼4.
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cardiac recovery from infarction by suppression of Ly6Clow Mo/
Mp-mediated angiogenesis and cardiac ﬁbrosis in mice
(Supplementary Table 3).
Given that Ep3 deﬁciency inhibited VEGF expression in
reparative Ly6Clow Mps, we tested the effect of the Mp Ep3
receptor on angiogenesis in vitro. Indeed, VEGF expression was
diminished at both the mRNA (Supplementary Fig. 14a) and
protein levels (Supplementary Fig. 14b,c) in cultured Mps from
Ep3F/F;LysMCre mice. In a cultured three-dimensional angiogen-
esis model using HUVECs, their sprouting and tube structure
formations were markedly reduced when co-cultured with
peritoneal Mps from Ep3F/F;LysMCre mice compared to those
in models co-cultured from Ep3F/F controls (Supplementary
Fig. 14d–g).
To validate the role of Ep3 receptor in Mos/Mps, we examined
whether bone marrow transplantation (BMT) from wild-type
(WT) donors could rescue the defective function of Ly6Clow
Mos/Mps in Ep3 knockout (KO) mice. Genotyping of both tail
specimens and blood samples veriﬁed successful BM reconstitu-
tion (Fig. 4a). Notably, total Ly6Clow, not Ly6Chigh Mos/Mps
recruited in ischaemic hearts were signiﬁcantly reduced in WT
mice which underwent BMT from Ep3 KO mice BM (KO-WT)
(Fig. 4b–d). Moreover, the decreased expression of both VEGF
and CX3CR1 in EP3 KO Ly6Clow Mos/Mps in the infarcted hearts
was completely rectiﬁed by WT BMT (WT-KO, Fig. 4e). In line
with the recovered inﬁltration and function of Ly6Clow Mos/Mps,
neovascularization in peri-infarct zones and cardiac function after
MI were signiﬁcantly improved in WT-KO mice as compared
with that in KO-KO mice (Fig. 4f–i, Supplementary Table 4).
Ep3 deﬁciency inhibits CX3CR1 and VEGF expression in Mps.
Reparative Ly6Clow Mo/Mp recruitment during inﬂammation,
including that post MI, depends on the CX3CR1 receptor6. We
detected striking downregulation of CX3CR1 and VEGF
expression in peritoneal Mps isolated from Ep3F/F;LysMCre mice
challenged by zymosan at both 48 h (Fig. 5a, Supplementary
Fig. 15a) and 96 h (Fig. 5b, Supplementary Fig. 15b) and in
cultured Ep3-deﬁcient Mps (Ep3F/F;LysMCre mice) treated by
PGE2 (Fig. 5c, Supplementary Fig. 15c). CCR2, the receptor for
monocyte chemoattractant protein-1 (MCP-1) that mediates
pro-inﬂammatory Ly6Chigh Mo/Mp recruitment, was not altered
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signiﬁcantly in Ep3-deﬁcient Mps (Fig. 5a–c). Accordingly, the
migration of Ep3-deﬁcient Mps in Boyden chambers was notably
restrained in Ep3-deﬁcient Mps with and without PGE2
stimulation (Fig. 5d).
Previously, we demonstrated that the Ep3 receptor mediates
TGFb1 signalling in pulmonary vascular smooth muscle cells by
activation of Rho/ROCK19. Similarly, TGFb1 signalling
(phosphorylation of Smad2 and Smad3) was inhibited in Ep3-
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deﬁcient Mps both in vivo and in vitro (Fig. 5a–c, Supplementary
Fig. 15a–c). Additionally, Ep3 deletion suppressed mouse Mp
migration in response to PGE2 (Fig. 5d). In human blood
CD14dimCD16þ Mos are similar to reparative Ly6Clow mouse
Mos (ref. 20). Ep3 agonist sulprostone promoted the migration
of human CD14dimCD16þ Mos, while Ep3 inhibitor L798106
suppressed CD14dimCD16þ Mo migration (Supplementary
Fig. 16a,b). Likewise, Ep3 receptor was also involved in regu-
lation of CX3CR1 expression in human Mos (Supplementary
Fig. 16c). To investigate whether TGFb1 signalling is involved
in Ep3-mediated regulation of CX3CR1 and VEGF expression
in Mos/Mps, we created an Mp-speciﬁc Ep3a transgenic
(Mp-EP3Tg) mouse model using the CD68 promoter (Supple-
mentary Fig. 17a–d). Indeed, overexpression of Mp-Ep3a induced
activation of TGFb1 signalling and elevated expression of both
VEGF and CX3CR1 in Mps (Fig. 5e–h, Supplementary Fig. 18),
and therefore increased PGE2-induced Mp migration (Fig. 5i),
promoted inﬁltration of Ly6Clow Mos/Mps (Fig. 6a–c) and
angiogenesis (Fig. 6d–f) in the infarcts, and facilitated cardiac
recovery after MI (Fig. 6g). Interestingly, inhibition of TGFb1
signalling markedly diminished the induction of VEGF and
CX3CR1 expression (Fig. 5e–h) and augmented migration
capacity in vitro in Ep3a-overexpressed Mps (Fig. 5i), retarded
the increased Ly6Clow Mos/Mps accumulation in infarcts
(Fig. 6c), and enhanced neovascularization in peri-infarct zones
and cardiac function in Mp-Ep3aTg mice (Fig. 6d–g, Supple-
mentary Table 5). We then tested whether the TGFb1 pathway
is implicated in Mp-Ep3-mediated angiogenesis using an
Mp/HUVEC co-culture system. As shown in Supplementary
Fig. 19a–c, forced expression of Ep3a in Mps increased VEGF
expression at both the mRNA and protein levels, while the
TGFb1 signalling blocker SB525334 attenuated the elevated
VEGF expression in Mp-Ep3Tg mice. Moreover, more sprouts
and tubal structures from HUVECs containing beads were
formed in culture with Mps fromMp-Ep3Tg mice than with those
from WT controls (Supplementary Fig. 19d–g). Again, these
differences were lost by the addition of SB525334 (Supplementary
Fig. 19d–g). Thus, Ep3-mediated reparative Ly6Clow Mo/Mp
recruitment and neovascularization in infarcted hearts is depen-
dent on TGFb1 signalling.
CX3CR1 and VEGF are downstream targets of TGFb1.
Through the PWMScan tool, 4 and 2 potential Smad binding
elements (SBEs) were predicted in the promoter of murine Cx3cr1
(S1–4) and Vegf (S10–20) genes, respectively (Fig. 7a,b). However,
the fragments containing S3 and S4 SBEs in the promoter of
Cx3cr1 were detected in the anti-Smad2/3 immunocomplex by
Chip assay in mouse RAW264.7 cell line (Fig. 7c). Activation of
TGFb1 signalling by co-transfection of the TGFb receptor Alk5
or addition of exogenous TGFb1 markedly enhanced luciferase
activities in the Cx3cr1 promoter (S3þ S4) containing reporter-
transfected RAW264.7 cells, both of which could be speciﬁcally
blocked by a TGFb1 inhibitor (Fig. 7d). Mutation of either S3 or
S4 signiﬁcantly weakened the TGFb1 and Alk5 co-transfection-
induced luciferase activities in RAW264.7 cells as compared to
these of WT fragment (S3þ S4) transfected cells (Fig. 7e).
Moreover, Ep3 inhibition also suppressed S3þ S4 promoter-dri-
ven activity in a dose-dependent manner (Fig. 7f). Similarly, two
SBEs (S10 and S20) were identiﬁed in the VEGF promoter region
by Chip and luciferase assays (Fig. 7g–i) in RAW264.7 cells.
Moreover, 1 and 5 potential SBEs were predicted in the promoter
of human CX3CR1 (hS) and VEGF genes (hS10–hS50, Fig. 7j,k),
respectively. Using a human THP-1 cell line, we identiﬁed one
(hS, Fig. 7l–n) and three (hS30–hS50, Fig. 7o–q) functional SBEs in
promoter of human CX3CR1 and VEGF genes, respectively.
Therefore, activation of the EP3 receptor induces CX3CR1 and
VEGF expression in Mps through TGFb1 signalling and subse-
quently promotes Ly6Clow accumulation after MI and peri-infarct
angiogenesis (Fig. 7r).
Discussion
PGE2 is implicated in the regulation of multiple aspects of
inﬂammation by tuning the functions of different immune cells,
including Mos/Mps21. Mos/Mps are a dominant source of PGE2
at sites of inﬂammation22. In mice, Mos/Mps can be divided
into two subsets based on the expression level of Ly6C
(pro-inﬂammatory Ly6Chigh and less inﬂammatory and patro-
lling Ly6Clow)6. In humans, CD14þCD16 Mos are similar to
murine Ly6Chigh cells, while CD14dimMos are similar to murine
Ly6ClowMos20. We found that Ep3 mediates recruitment and
reparative function of Ly6Clow Mo/Mp in inﬂamed tissues.
Activation of the Ep3 receptor upregulates expression of the Mp
chemokine receptor CX3CR1, which mediates Ly6Clow Mo
inﬁltration in hearts after MI6. In addition, the Mo/Mp Ep3
receptor also mediates expression of the pro-angiogenic factor
VEGF, which stimulates wound healing after MI by enhancing
neovascularization in peri-infarct zones in mice. In agreement
with our observations, tumour-derived PGE2 promotes
differentiation of tumour-associated suppressive Mps (M2-like
Mps) from the Mos inﬁltrated in tumours23. And the PGE2–Ep3
axis also mediates recruitment and maturation of mast cells upon
repeated allergen challenges24.
The Ep3 receptor mediates multiple cellular cascades by
activating different types of heterotrimeric G proteins, including
Gas, Gai and Ga12/13 (refs 25,26). We recently discovered that
activation of the Ep3 receptor augments Rho/ROCK-dependent
Figure 3 | Ep3 deletion retards cardiac recovery after MI in mice. (a) Gating strategy for CD11bþCD115þ Ly6GLy6Chigh and CD11bþCD115þ Ly6G
Ly6Clow Mos/Mps in hearts after left anterior descending (LAD) artery ligation in mice. (b–d) Effect of Ep3 deletion on recruitment of total Mos/Mps (b),
Ly6Clow (c) and Ly6Chigh (d) Mos/Mps in injured hearts of mice after MI. Data represent mean±s.e.m. *Po0.05 versus Ep3F/F (unpaired two-tailed t-
test); n¼ 5–8. (e) mRNA expression levels of VEGF, ﬁbrolast growth factor (FGF), hepatocyte growth factor (HGF), platelet-derived growth factor-bb
(PDGFbb), and CX3CR1 in Mos/Mps sorted from hearts in Ep3F/F and Ep3F/F;LysMCre mice at day 14 post MI. Data represent mean±s.e.m. *Po0.05 versus
Ep3F/F (unpaired two-tailed t-test); n¼ 10. (f) Representative immunostaining for CD68 (red) and VEGF (green) in peri-infarct zones of hearts from Ep3F/
Fand Ep3F/F;LysMCre mice at day 14 post MI. The solid box outlines the region enlarged to the right. Yellow arrow, CD68þ/VEGFþ cell. Scale bar, 5 mm.
(g) Quantitation of VEGF signalling in CD68þ cells in injured hearts as shown in f. Data represent mean±s.e.m. *Po0.05 versus Ep3F/F (unpaired two-
tailed t-test); n¼ 5. (h) Representative immunostaining of CD31 (red) and proliferating cell nuclear antigen (PCNA, green) in peri-infarct zones of hearts
from Ep3F/F and Ep3F/F;LysMCre mice at day 14 post MI. The solid box outlines the region enlarged to the right; yellow arrow, CD31þ/PCNAþ cell. Scale bar,
20mm. (i,j) Quantitation of CD31þ areas (i) and PCNAþCD31þ cells (j) in injured hearts as shown in h. Data represent mean±s.e.m. *Po0.05 versus
Ep3F/F (unpaired two-tailed t-test); n¼ 7. (k) Representative echocardiography images with M-mode views of infarcted hearts from Ep3F/F;LysMCre and
Ep3F/Fmice on day 14 after MI. Arrows and lines mark left ventricular inner diameters (LVID) in systole (dashed) and diastole (ﬁrm). (l) Cardiac function of
Ep3F/F;LysMCre and Ep3F/F mice at different timepoints after MI. EF, ejection fraction. *Po0.05 versus Ep3F/F (unpaired two-tailed t-test); n¼ 9–13.
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TGFb1/Smad2/3 signalling to facilitate hypoxia-induced vascular
ﬁbrosis by coupling with Ga12 in pulmonary arterial smooth
muscle cells19. Indeed, Ep3 deﬁciency also results in decreased
Rho activity and subsequent suppression of TGFb1 signalling in
both peritoneal and infarcted myocardium-derived Mps, whereas
forced expression of the Ep3 receptor in Mos/Mps ampliﬁed
TGFb1/Smad2/3 signalling. Furthermore, we identiﬁed
conservative SBEs in the promoter regions of both human and
mouse CX3CR1 genes coding a chemokine receptor for CX3CL1,
which governs Ly6Clow Mo migration into inﬂammation sites6.
Thus, the Ep3 receptor regulates Ly6Clow Mo/Mp recruitment
into the ischaemic myocardium through the TGFb1/CX3CR1
pathway. Interestingly, CX3CR1/CX3CL1 interactions confer a
vital survival signal for Mos/Mps, whose complete disruption
causes death of peripheral Mos27 and renal resident Mps28,29 and
forms cells in atherosclerosis plaques27. We failed to observe
marked death and/or apoptosis of peripheral Mos or Mps in the
injured myocardium in Mp-Ep3-deﬁcient mice with reduced
expression of CX3CR1 in Mos/Mps, which is consistent with
the phenotypes presented in CX3CR1 heterozygous mice
(CX3CR1GFP/þ )27,30. In addition, CX3CR1 deﬁciency appears
to impair reparative functions of macrophages (pro-ﬁbrosis,
proangiogenesis, and phagocytosis) in a variety of disease
processes, such as skin wound healing31–33. In an experimental
MI mouse model, Mo/Mp Ep3 deletion retarded myocardial
healing by inhibiting peri-infarct angiogenesis. Further
mechanistic analysis revealed that Ep3 receptor activation in
Mos/Mps promotes TGFb1/Smad pathway-derived VEGF
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Figure 7 | CX3CR1 and VEGF are TGFb1-targeting genes in mice and humans. (a,b) Schematic illustration of predicted Smad binding elements (SBEs) in
the promoter of murine Cx3cr1 (a) and Vegf (b) genes. S¼ SBE. (c) Gel electrophoresis of PCR-ampliﬁed SBE-containing fragments in the promoter of the
murine Cx3cr1 gene using anti-Smad2/3 immunoprecipitation. (d) Effect of the TGFb1 blocker SB525334 on S3þ S4 fragment-mediated luciferase activity.
*Po0.05 as indicated (unpaired two-tailed t-test); n¼4. (e) Effect of mutations of S3 (mS3) and S4 (mS4) on S3þ S4 fragment-mediated transcription
activity. *Po0.05 versus the S3þ S4 group, n¼4. (f) Effect of L-798,106 on S3þ S4 fragment-mediated luciferase activity in RAW264.7 cells. *Po0.05
versus no treatment (unpaired two-tailed t-test);n¼4. (g) Gel electrophoresis of PCR-ampliﬁed SBE-containing fragments in the promoter of the murine
Vegf gene using anti-Smad2/3 immunoprecipitation. (h) Effect of SB525334 on the functional SBEs (S10 þ S20) in murine Vegf promoter. *Po0.05 as
indicated (unpaired two-tailed t-test); n¼4. (i) Effect of L798106 on S10 þ S20 fragment-mediated luciferase activity in RAW264.7 cells. *Po0.05 versus
no treatment (unpaired two-tailed t-test); n¼ 5. (j,k) Schematic illustration of the predicted SBE(s) on the human CX3CR1 gene (hS, (j)) and the human
VEGF gene (hS0 , (k)). (l) Gel electrophoresis of PCR-ampliﬁed SBE-containing fragments in the promoter of the human CX3CR1 gene. (m) Effect of
SB525334 on hS-mediated transcription activity in THP-1 cells. *Po0.05 as indicated (unpaired two-tailed t-test); n¼ 5. (n) Effect of L-798,106 on hS-
mediated transcription activity in THP-1 cells. *Po0.05 versus no treatment (unpaired two-tailed t-test); n¼ 5. (o) Gel electrophoresis of PCR-ampliﬁed
SBE-containing fragments in the promoter of the human VEGF gene. (p) Effect of SB525334 on hS30–hS50 fragment-mediated transcription activity in THP-1
cells. *Po0.05 as indicated, n¼ 5. (q) Effect of L-798,106 on hS30–hS50 fragment-mediated transcription activity in THP-1 cells. *Po0.05 versus no
treatment (unpaired two-tailed t-test); n¼ 5. (r) Schematic diagram of EP3-mediated regulation of CX3CR1 and VEGF genes in Mos/Mps through TGFb1.
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transcription. As previously reported34, we validated multiple
conservative SBEs in the VEGF gene promoter in both mouse and
human Mp cell lines, but not in inﬁltrated cardiac Mo/Mps due to
technical difﬁculties. Taken together, the data suggest that
activation of the Mo/Mp Ep3 receptor facilitates wound
healing after MI by increasing CX3CR1-mediated Ly6Clow
Mo recruitment and VEGF-induced angiogenesis, which are
TGFb1/Smad pathway-dependent.
Cardiac PGE2 generation increases during acute MI17. Despite
the expression of multiple PGE2 receptor subtypes in hearts,
selective stimulation of the Ep3 receptor displays cardio-
protection against ischaemia/reperfusion injury in different
mammalian species35–38. For instance, pharmacological
activation of Ep3 receptor reduces myocardial infarct size in
rodents by activation of protein kinase C (PKC) and the opening
of ATP-sensitive potassium channels in cardiomyocytes36,37. We
found that inactivation of Ep3 in Mos/Mps impairs myocardial
repair after acute ischaemia; in contrast, forced activation of
Ep3-mediated signalling in Mos/Mps accelerates healing in mice
after MI by increasing recruitment of reparative Mos/Mps and
secretion of proangiogenic VEGF. Thus, Ep3 mediates cardiac
protection against ischaemia, at least in part through activation of
reparative Mos/Mps. In addition, Ep3 is also involved in
regulation of lipid metabolism. Global Ep3 deletion promotes to
diet-induced obesity and exaggerates ectopic lipid deposition such
as in skeletal muscle in mice39,40. Hepatic Ep3 deﬁciency
exacerbated atherosclerosis in hyperlidemic mice through
suppression of biliary cholesterol secretion in mice41. However,
Ep3 mediates vasoconstriction42, and genetic deletion of Ep3
receptor increases bleeding tendency38 and reduces athero-
sclerosis-related thrombosis43, suggesting Ep3 involvement in
platelet activation. Therefore, the potential efﬁcacy of speciﬁc
activation of Ep3 receptor in cardiac recovery after MI requires
further investigations.
In summary, we showed that the PGE2–Ep3 axis in Mo/Mp
exerts a beneﬁcial effect on myocardial recovery in response to
acute ischaemia through TGFb1-mediated activation of repara-
tive Ly6Clow Mos/Mps. These observations suggest Ep3 receptor
and its downstream pathway maybe a promising therapeutic
target for acute MI.
Methods
Mice. All animal procedures were approved by the Institutional Animal Care and
Use Committee of the Institute for Nutritional Sciences, Chinese Academy of
Sciences, as well as the number of animals to be used were approved based on the
expected effects size. Ep3F/F (Ep3F/F)44 and Ep3 knockout (KO) mice19 were
maintained on C57BL/6 background, LysMCre transgenic mice (C57BL/6, The
Jackson Laboratory) were crossed Ep3F/F to obtain Ep3F/F;LysMCre mice.
Echocardiography. High-resolution echocardiography imaging system (Vevo 770,
Visual Sonics) were used with M-mode analysis to assess mouse cardiac function.
Both male and female mice (10–14 weeks old) were anaesthetized by isoﬂurane
inhalation (1–2%) and heart rate was maintained at 350–500 b.p.m. The mitral
valve leaﬂet was visualized and cardiac function was evaluated in the parasternal
long axis view as previously described45.
Macrophage-speciﬁc Ep3a transgenic mice. Macrophage (Mp)-speciﬁc Ep3a
transgenic mice were generated as described previously46. Brieﬂy, Ep3a cDNA was
cloned into the CD68 promoter-contained vector, and the successful construct was
injected into C57BL6 zygotes to obtain founder mice.
Mouse model of myocardial infarction. Left anterior descending (LAD)
ligation was used in both male and female mice (8–12 weeks old) to induce MI.
Brieﬂy, mice were anesthetized with isoﬂurane (2%) using an induction chamber,
and the LAD coronary artery was completely ligated to induce left ventricular
ischaemia47.
Myocardial necrotic injury was assessed by nitro blue tetrazolium (NBT)
staining as previously reported48. Brieﬂy, hearts were collected 12 or 24 h after LAD
ligation and then cut into slices about 2mm thick. Slices were incubated in
0.5mgml 1 NBT in phosphate buffer at pH 7.4 and 37 C for 20min. The
unstainedportion (necrotic) could be separated from the dark blue stained
(non-necrotic) region. The percentage of necrotic area was determined by dividing
the weight of the necrotic tissue by the total weight and multiplying by 100.
As for infarction analysis, hearts were dissected at day 14 after infusion of
10% evans blue (100 ml) and frozen at  20 C for 30min, then cut into 2-mm-
thick slices from apex to base. The slices were incubated in 1% triphenyltetrazolium
chloride at 37 C for 30min to identify non-infarcted and infarcted areas. The
normal myocardium was then recognized by red staining by triphenyltetrazolium
chloride, while infarcted tissue presented as milky white. Infarct area was calculated
as the ratio of the infarct area to the total slice areas previously described49.
Enzyme-linked immunosorbent assay. Serum was collected from retro-orbital
blood from mice 14 days after MI induction. Levels of the heart failure marker
brain natriuretic protein in serum was measured by enzyme-linked immunosor-
bent assay, according to the manufacturer’s instructions (R&D Systems).
Immunoﬂuorescence staining. For immunoﬂuorescence, heart sections (8 mm)
were incubated with primary antibodies against CD68 (Serotec, 1:200), CD301
(Biolegend, 1:200), PCNA (CST, 1:800), CD31 (RD, 1:200), VEGF (Proteintech,
1:200), SMA (Sigma, 1:500), CollagenI(Proteintech,1:200), THBS1( Proteintech,
1:200) and Alexa Fluor 488/594/633-conjugated secondary antibodies (Invitrogen,
Carlsbad, CA, 1:1,000) for 1 h at room temperature, respectively. The embedded
hearts were washed and stained with DAPI (Millipore, MA). Images were captured
under a Olympus (FV1000) laser-scanning confocal microscope from each heart
section for further analysis. Positive staining area and relative mean ﬂuorescent
intensity were measured using Image-Pro Plus software 6.0 (Media Cybernetics,
Rockville, MD, USA)50.
For immunocytochemistry, primary Mos/Mps grown on slides were stimulated
with or without PGE2 and then ﬁxed with 4% paraformaldehyde. The slides were
blocked in TBST containing 1% bovine serum albumin after washing, incubated
with primary antibodies against CD68 (Serotec, 1:200) or VEGF (Proteintech,
1:200) overnight at 4 C, stained with a secondary antibody for 2 h at room
temperature, and photographed using ﬂuorescent microscopy as described above.
At least ﬁve random images were taken in region of each slide and positive
signalling was quantiﬁed as previously described51.
Bone marrow transplantation. Same sex BMT was performed as previously
described52. In brief, mice (6–8 weeks old) were euthanized and bone marrow
(BM) cells were collected from femurs and tibias. Recipient mice were lethally
irradiated (one 5.0-Gy dose and another 4-Gy dose administered 1.5 h apart) from
a 137Cs source (MDS Nordion, Ottawa, Ontario, Canada) and transplanted with
5 106 donor BM cells via tail vein injection to reconstitute the hematopoietic
system. Eight weeks after transplantation, BMT chimeric mice were used for
experiments.
Fluorescence activated cell sorting analysis. Cells collected from mice were
stained with ﬂuorochrome-conjugated antibodies, according to the manufacturer’s
protocols. FITC-conjugated antibodies to CD11b (M1/70,1:50), Brilliant Violet
421-conjugated antibodies to CD115 (AFS98,1:50), APC-conjugated antibody to
Ly6C (HK1.4,1:50), APC-CY7-conjugated antibody to Ly6G (1A8,1:50) were
purchased from Biolegend. Flow cytometry was performed using a BD FACS Aria
ﬂow cytometry system (BD Biosciences, San Jose, CA), and data were analysed with
FlowJo software. Total viable leukocyte number was determined with the trypan-
blue exclusion method. Leukocyte subpopulation numbers were calculated as total
leukocytes multiplied by per cent cells within the selected population gated by
FlowJo software (Tree Star, Ashland, Ore) and all FACS gates for ﬂuorochrome-
labelled monoclonal antibodies were deﬁned using appropriate isotype controls.
Peritoneal inﬂammation. Peritonitis was induced by intraperitoneal injection of
zymosan (2 mgml 1; Sigma-Aldrich, St Louis, MO). Peritoneal cells at different
time points after the zymosan challenge were isolated for FACS analysis.
Cell extract and culture. Primary Mos/Mps were prepared from the abdominal
cavity and cultured in 10% FBS 1640 medium. A single-cell suspension from
infracted hearts was prepared as previously described53. Brieﬂy, the hearts were
dissected, carefully cut into small pieces with ﬁne scissors, and enzymatically
digested with 450Uml 1 of a cocktail of type I collagenase, 125Uml 1 type IX
collagenase, and 60Uml 1 DNase I, and 60Uml 1 hyaluronidase I-S ( Sigma, St
Louis, MO) for 1 h at 37 C. After digestion, the tissues were passed through 70-mm
cell strainers, washed, and stained with antibody for FACS analysis.
Western blot. Cells were extracted in lysis buffer containing protease inhibitors.
Protein concentration was determined by the BCA method using the Pierce BCA
Protein Assay Kit (Pierce, Rockford, IL). Equal quantities of proteins from total cell
lysates were separated by 10% SDS–PAGE gel and probed with antibodies against
CX3CR1 (1:500, Abcam), CCR2 (1:500, Abcam), p-Smad2 (1:1,000, CST), p-Smad3
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(1:1,000, CST), T-Smad3 (1:1,000, CST), T-Smad2/3 (1:1,000, CST), VEGF
(1:1,000, Proteinteh), and GAPDH (1:2,000, CST), and then conjugated with an
HRP-labelled secondary antibody in blocking buffer for 1–2 h at room temperature.
Proteins were detected using an ECL detection kit (Super Signal West Pico
Chemiluminescent Substrate), and signalling was quantiﬁed by image J software
and presented as normalized arbitrary units. The uncropped scans of all western
blots are supplied in Supplementary Fig. 20.
Macrophage (Mp) migration assay. Primary Mps (1000,000 cells per well) were
pretreated with 10 nM PGE2 in serum-free DMEM media for 24 h and then seeded
on cell culture inserts (Millicell-PCF, Millipore) with porous polycarbonate ﬁlters
(8-mm pore size) in 24-well plates. DMEM with CX3CL1 (20 ngml 1) was placed
in the lower chamber at 37 C and 5% CO2. After 6 h, cells that migrated to the
bottom well of the transwell chamber were ﬁxed in paraformaldehyde (Thermo
Scientiﬁc) and stained with DAPI for quantitation. The chemotactic index is the
ratio of migrated Mps to total Mps.
Quantitative RT-PCR analysis. RNA was isolated from tissues and cells using the
Trizol reagent (Invitrogen, Carlsbad, CA), and cDNA was synthesized by reverse
transcription kits (Takara, Dalian, China). All mRNA expression levels were
normalized by comparing them to the housekeeping gene GAPDH. All RT-PCR
primers are listed in Supplementary Table 6.
Prediction of transcription-factor binding sites. The fragment between  2,000
and ±500 bp of the transcription start sites of the CX3CR1 and VEGF gene from
the UCSC genome browser database was analysed for putative Smad binding
element (SBE) motifs in TRANSFAC version 10.2 using PWMSCAN54. A match
score with a P value o5 10 6 was considered to indicate a high-conﬁdence
binding site prediction.
Chromatin immunoprecipitation (Chip) assays. Chip assays were conducted
with a Magna ChIPTM A/G chromatin immunoprecipitation kit (Millipore)
according to the manufacturer’s protocol. In brief, RAW264.7 and THP-1 cells
were stimulated for 24 h by TGFb1. Cells were then cross-linked with for-
maldehyde (1% ﬁnal concentration), and the pellet was lysed and sonicated to
shear the chromatin into 200–1,000-bp fragments. The lysates were diluted using a
chromatin dilution buffer. The chromatin extract was incubated with 10 mg of rat
anti-Smad2/3 antibody (Abcam) or rat IgG (negative control) at 4 C with rotation
overnight, and the antibody–antigen–DNA complex was collected by protein
G-agarose. The immunocomplexes were washed and the protein–DNA complexes
were eluted, and then proteinase K was used to reverse the cross-linking of protein–
DNA complexes to free up DNA. DNA was puriﬁed with the DNA puriﬁcation kit
(Promega), dissolved in elution buffer, and used for quantitative PCR analysis. The
primers used for ampliﬁcation of SBE-containing fragmentsof CX3CR1 and VEGF
genes are listed in Supplementary Table 7.
Luciferase reporter assay. Mouse macrophage cell line RAW264.7(ATCC
TIB-71) and Human monocyte cell line THP-1(ATCC TIB-202) were tested every
3 months for mycoplasma contamination by performing a PCR on the cell
supernatant. They were seeded into 24-well plates and grown to 70% conﬂuence.
Luciferase reporter or control empty vector plasmids were co-transfected with
RPL-TK (internal plasmid) (20:1) into cells by using a lipofectamine 2000 trans-
fection reagent (Invitrogen). Cells were cultured in a medium containing 1% FBS
and lysed 24 h after transfection. The Ep3 antagonist L798106 (Cayman,
0.1–10 mmol) or TGFb1 (Selleck, 10 ngml 1) was used to treat cells overnight 16 h
after transfection. Luciferase activities were monitored with a dual luciferase
reporter assay kit (Promega).
Plasmid construction. Mouse Cx3cr1 promoter DNA fragments ( 453 to
124 bp) and Vegf promoter DNA fragments (–1,216 to 399 bp) were ampliﬁed from
mouse macrophage genomic DNA by PCR. The two promoter fragments were
subcloned into pGL3 (Promega). The reporter with the insert of a fragment of
 453 to 124 of CX3CR1 gene was named S3þ S4. Mutations were introduced into
the third (mS3) and fourth (mS4) SBEs of the CX3CR1 promoter by QuikChange
site-directed mutagenesis (Stratagene, La Jolla, CA). Human CX3CR1 promoter
DNA fragments ( 196 to 107 bp) and VEGF promoter DNA fragments ( 1,278
to 134 bp) were ampliﬁed and subcloned into the PGL3 vector for the reporter
assay. The PCR primers for promoter subcloningare listed in Supplementary
Table 8.
In vitro HUVEC ﬁbrin gel bead assay. Human vascular endothelial cells
(HUVECs), from PromoCell (C-12200) were mixed with dextran-coated Cytodex 3
microcarriers (GE) at a concentration of 400 HUVECs per bead in 1.5ml of EGM-
2 medium (Clonetics, Walkersville, MD). Beads with cells were shaken gently at
37 C and 5% CO2 every 20min for 4 h. After incubating, beads with cells were
transferred to a T2 tissue culture ﬂask (Corning) and left overnight in 5ml of
EGM-2 at 37 C and 5% CO2. After that, beads with cells were washed three times
with 1ml of EGM-2 and re-suspended at a concentration of 200 cell-coated beads
per ml with 2.5mgml 1 of ﬁbrinogen (Sigma) and 0.15 units ml 1 of aprotinin
(Sigma). Five hundred microlitre of ﬁbrinogen/bead solution was added to 0.625
units of thrombin (Sigma) in one well of a 24-well tissue culture plate. The
ﬁbrinogen/bead solution was allowed to clot for 5min at room temperature and
then at 37 C and 5% CO2 for 20min. One millilitre of EGM-2 (which contains 2%
FBS) with or without 0.15 units ml 1 aprotinin was added to each well and
equilibrated with the ﬁbrin clot for 30min at 37 C and 5% CO2; 106 macrophage
cells were plated on top of the clot. Assays were terminated at day 7 for immu-
nostaining and imaging55.
PG extraction and analysis. Hearts collected from mice 14 days after MI
were homogenized, and 500 ml supernatant were used for PG extraction. Heart
prostanoid metabolites were extracted and quantitated using liquid chromato-
graphy/mass spectrometry/mass spectrometry (LC/MS/MS) analyses. In brief,
following internal standards (2ml), 40ml citric (1M) and 5 ml BHT were added to
the sample and then strenuously vibrated with 1ml solvent (normal hexane: ethyl
acetate, 1:1) for 1min. After centrifugation (6,000 gmin 1) for 10min, the
supernatant organic phase was collected and dried under a gentle stream of
nitrogen, dissolved in 100 ml 10% acetonitrile in water. Production was normalized
to total protein.
Isolation of human blood Mos. Human peripheral blood mononuclear cells
(PBMCs) were purchased from Zenbio and resuspended (106 cells/10 ml) in sorting
buffer (2mM EDTA, 0.5% BSA in PBS) and stained with anti-human antibodies
(Biolegend) speciﬁc for anti-CD14 and anti-CD16. Stained cells were ﬁltered
(70 mm) and sorted on a BD FACSAria II cell sorter using appropriate colour
compensation for correcting spectral overlap and autoﬂuorescence. Isolated
CD14dimCD16þ Mos were used for subsequent experiments.
Mo adoptive transfer. For zymosan-induced peritonitis mouse model, Mo subsets
were sorted from spleens of EP3F/F and EP3F/FLysCre mice, then labelled with cell
proliferation dye eFluor 670 (eBioscience) and injected into C57/BL6 mice 6 h after
zymosan challenge by tail vain.
For MI model, Mo subsets were collected from CD45.2þ mice as previously
described10, and injected into CD45.1þ mice on day 3 post MI. Infarcted hearts at
day 6 post MI were dissected for preparation of single-cell suspension and ﬂow
cytometric analysis.
Histological analysis. The infacted hearts were collected at indicated time points
and embedded in the parafﬁn. The sections (6 mm) were stained with hematoxylin–
eosin and Masson trichrome (Sigma). IPP software was used to analyse the necrotic
area or collagen density as described56.
Isolation of neutrophils and function assay. APC-conjugated antibody to
CD11b (M1/70),PE-conjugated antibody to CD45(30-F11) and APC-CY7-
conjugated antibody to Ly6G (1A8)were purchased from Biolegend. Neutrophils
were sorted from injured hearts by FACS and calculated by FlowJo software
(Tree Star, Ashland, Ore). Ly6G (ab25377) were purchased for immuno-
ﬂuorescence in mice heart after MI. For reactive oxygen species (ROS) measure-
ment, puriﬁed neutrophils were loaded for 20min at 37 C with dichloro-dihydro-
ﬂuorescein diacetate (DCFH-DA). Cells were washed and then production of ROS
was quantiﬁed via ﬂow cytometry by measurement of DCF. To detect intracellular
myeloperoxidase, 5 104 neutrophils were lysed with TBS containing 0.2% Triton
X-100 (50ml) and the myeloperoxidase activity was measured as previously
described57.
Statistics. Prism software (GraphPad Prism version 5.0) was used for statistical
analysis. Results are shown as mean±s.e.m. Two-tailed student’s t-testing and one-
or two-way ANOVA with Bonferroni post-hoc analyses were used for comparisons
between different groups. A P value less than 0.05 was considered signiﬁcant.
Sample sizes were designed with adequate power according to the literature and
our previous studies. Randomization and blinding strategy was used whenever
possible.
Data availability. All the data supporting the ﬁndings of this study are either
included in the manuscript and its Supplementary Information Files, or can be
obtained from the corresponding author upon reasonable request.
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